Boston Scientific Q2 Adjusted Earnings, Revenue Rise; Lowers 2026 Guidance

MT Newswires Live
Jul 29

Boston Scientific (BSX) reported Q2 adjusted earnings Wednesday of $0.86 per share, up from $0.75 a year earlier.

Analysts polled by FactSet expected $0.83.

Net sales for the quarter ended June 30 were $5.44 billion, up from $5.06 billion a year earlier.

Analysts surveyed by FactSet expected $5.36 billion.

For Q3, the company expects adjusted EPS of $0.80 to $0.82 and net sales growth of 3% to 5%. Analysts polled by FactSet expect $0.84 and $5.38 billion, respectively.

For 2026, the company lowered its adjusted EPS guidance to $3.28 to $3.32 from $3.34 to $3.41. Analysts polled by FactSet expect $3.36.

Full-year net sales are now expected to grow about 5.5% to 6.5%, down from the previous projection of 7% to 8.5% growth.

Shares of the company were up 3.5% in Wednesday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10